MET and non-small cell lung carcinoma: Tepotinib (Tepmetko®). This compound is a phenylmethyl-pyrimidine derivative developed to disrupt MET phosphorylation that received approval from the FDA and the Japanese Ministry of Health, Labour and Welfare for the treatment of patients with metastatic NSCLC harboring METex14 skipping alterations who progressed following platinum-based cancer therapy [700].